The board of directors of Vantek Pharmaceuticals recently voted to rescind a substantial performance bonus previously awarded to its chief research officer. The bonus had been granted after the officer successfully accelerated the development of a lucrative cardiovascular drug. However, subsequent independent regulatory audits revealed that the accelerated timeline was achieved only because the research team bypassed several non-mandatory preliminary toxicity protocols, ultimately resulting in unexpected manufacturing delays and significant financial losses during commercial production. Because the research officer did not violate any mandatory regulatory guidelines or explicit contractual terms, several board members argued that the rescission was unfair. Nevertheless, the board's decision was entirely justified.
Which one of the following principles, if established, most helps to justify the board's decision to rescind the bonus?
- AAn institution is justified in revoking a previously granted performance reward only if the recipient of that reward engaged in deliberate violations of established regulatory standards.
- BAny researcher whose managerial decisions inadvertently lead to downstream commercial manufacturing delays should be permanently barred from receiving performance-based compensation across the industry.
- A governing board is justified in revoking a performance reward awarded for achieving an operational milestone if the discretionary methods used to attain that milestone directly result in substantial net operational losses.Answer
- DInstitutional boards should refrain from awarding performance bonuses to research personnel until all subsequent phases of commercial production have concluded without financial delay.
- EIf an administrative body imposes financial penalties on an employee whose conduct complied with all explicit contractual terms, the board must prove that the employee foresaw the exact monetary extent of the resulting damage.